Author  
Place of duty  
Title   진행성 유방암에서 Pirarubicin 의 임상연구 ( A Clinical Study with Pirarubicin in the Advanced Breast Cancer )
Publicationinfo   1993 Jan; 025(06): 935-941.
Key_word   Pirarubicin, Breast cancer, Chemotherapy
Full-Text  
Abstract   Adriamycin is regarded as one of the most active anticancer drug in the avanced breast cancer. But its usefulness is limited by its well known side effect. Pirarubicin, is one of new anthracyclin derivative, suggested less cardiac toxicity and favorable therapeutic efficacy. For the clinical assessment of the efficacy and toxicity of pirarubicin. We treated 25 patients in advanced or metastatic breast cancer with pirarubicin at 2l day interv#al for at least 3 cycles or until the development of progressive disease. The median age was 42 years old and 12 patients were premenopausaL Twelve patients had prior chemotherapy and ten had hormonal therapy. There is 24% overal response by pirarubicin but no complete response case is observed. Such side effects as leukopenia and gastrointestinal disturbances were observed but alopecia was mild and no cardiotoxicity wss seen in any of the patients. Hepatorenal function is not affected by pirarubicin. With the above clinical results in this short term trial, pirarubicin has less toxicity than adriamycin and the acceptable therapeutic effect in the advanced breast cancer.
저 자   오승택(Seong Taek Oh),정상설(Sang Seol Jung),신종태(Jong Tae Shin),김인철(In Chul Kim),김의동(Eui Dong Kim)